Oncofocus
  • Services
    • Primary Market Research
    • Competitive Intelligence
  • About
  • Blog
  • Reports
  • Careers
  • Contact
“So it is said that if you know your enemies and know yourself, you can win a hundred battles without a single loss.
​If you only know yourself, but not your opponent, you may win or may lose.
​If you know
neither yourself nor your enemy, you will always endanger yourself.”
​- Sun Tzu from Art of War

Melanoma Indication

29/10/2019

 

PD-1/PD-L1 Combination Strategies

​Malignant melanoma is a complex, multifactorial disease, which is responsible for up to 75% of skin cancer related deaths globally.

With the US FDA approval of ipilimumab (CTLA-4 targeting agent) in 2011 for the treatment of advanced melanoma patients, clinical research intensity has gradually shifted towards Immune Checkpoint Inhibitors (ICIs) & their Combination agents. 

After the approval of nivolumab and pembrolizumab (both are PD-1 targeting agents), it is imperative to understand how PD-1/PD-L1 clinical landscape is evolving in melanoma.
​
Picture
Read More

Comments are closed.

    Categories

    All
    BCMA
    CARTs
    Cervical Cancer
    Melanoma
    Multiple Myeloma
    PD-1 And PD-L1
    Pipeline Landscape

    Archives

    November 2019
    October 2019
    September 2019
    April 2019
    August 2017

Bangalore Office
Oncofocus Solutions Pvt Ltd, 

#4, II Floor, 5th Main, 9th Cross, Jaya Mahal Ext,
Bengaluru
, India 56 00 46

Tel. +91 89044 00482

E-mail: support@oncofocus.com
RFQ: rfq@oncofocus.com
​

Singapore Office (Sales)
Oncofocus Solutions Pte Ltd, 

51 Goldhill Plaza, 
#07-10/11
​Singapore 30 89 00
​



E-mail: support@oncofocus.com.sg
​RFQ: rfq@oncofocus.com
​

    Subscribe to our Newsletter

Subscribe to Newsletter
Tweets by oncofocus
  • Services
    • Primary Market Research
    • Competitive Intelligence
  • About
  • Blog
  • Reports
  • Careers
  • Contact